Raymond James Financial
CGON icon

Raymond James Financial’s CG Oncology CGON Stock Holding History

Raymond James Financial’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$925K Buy
13,015
+1,925
+17% +$126K ﹤0.01% 4055
2026
Q1 		$751K Buy
11,090
+2,787
+34% +$158K ﹤0.01% 4072
2025
Q4 		$345K Buy
8,303
+1,005
+14% +$41.6K ﹤0.01% 4484
2025
Q3 		$294K Buy
7,298
+6,998
+2,333% +$203K ﹤0.01% 4427
2025
Q2 		$7.8K Buy
+300
New +$7.23K ﹤0.01% 6028

Other funds holding CGON

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Raymond James Financial's CGON Position: Q2 2026 in Review

Raymond James Financial increased its CG Oncology (CGON) stake by 17% in Q2 2026, buying an estimated $126K and bringing the position to 13,015 shares worth $925K. The position accounts for ﹤0.01% of the portfolio, ranked #4055.

Raymond James Financial first reported a position in CGON in Q2 2025 and has held it in 5 quarters since. 227 funds tracked by Wall St. Rank hold CGON as of Q2 2026.

  • Raymond James Financial held 13,015 shares of CG Oncology worth $925K as of Q2 2026.
  • Raymond James Financial bought 1,925 CG Oncology shares in Q2 2026, an estimated $126K.
  • CG Oncology made up ﹤0.01% of Raymond James Financial's portfolio in Q2 2026, its #4055 holding.
  • Raymond James Financial first reported a position in CG Oncology in Q2 2025 and has held it in 5 quarters since.
  • 227 funds tracked by Wall St. Rank held CG Oncology as of Q2 2026.

Based on Raymond James Financial's 13F filing for Q2 2026, filed 14 Aug 2026.